We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What We Expect From AbbVie's Immunology Segment in Q4
Read MoreHide Full Article
Key Takeaways
AbbVie's immunology segment, led by Skyrizi and Rinvoq, is expected to anchor Q4 and full-year 2025 results.
Model estimates project Q4 sales of $4.87B for Skyrizi and $2.33B for Rinvoq on strong IBD demand.
AbbVie faces rising competition, but new launches in UC and GCA are expected to support immunology momentum.
AbbVie (ABBV - Free Report) generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyrizi and Rinvoq. The robust demand for both drugs has helped the company return to top-line growth despite the U.S. loss of exclusivity for its flagship drug, Humira, three years ago. Investors will be most keen to know the sales numbers of these two drugs when the company reports fourth-quarter and full-year 2025 results on Feb. 4, 2025.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, and a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Our model estimates for Skyrizi and Rinvoq sales are pegged at $4.87 billion and $2.33 billion, respectively, for the to-be-reported quarter.Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC and Rinvoq in giant cell arteritis (GCA) indication, are expected to drive Q4 performance.
Beyond immunology, AbbVie has been expanding its presence in other therapeutic areas, notably neuroscience and oncology. Growth in its neuroscience franchise has been supported by increasing uptake of its oral migraine therapies, Ubrelvy and Qulipta. In oncology, the company has successfully broadened its portfolio beyond hematologic cancers into solid tumors, led by newer assets such as Elahere and Emrelis.
ABBV’s Competition in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Eli Lilly drug received FDA approval for the CD indication last year.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.50 times forward earnings, lower than its industry’s average of 17.91. The stock is also trading above its five-year mean of 13.55.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2025 has declined from $10.73 to $10.64, while those for 2026 have increased from $14.41 to $14.42 over the past 60 days.
Image: Shutterstock
Here's What We Expect From AbbVie's Immunology Segment in Q4
Key Takeaways
AbbVie (ABBV - Free Report) generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyrizi and Rinvoq. The robust demand for both drugs has helped the company return to top-line growth despite the U.S. loss of exclusivity for its flagship drug, Humira, three years ago. Investors will be most keen to know the sales numbers of these two drugs when the company reports fourth-quarter and full-year 2025 results on Feb. 4, 2025.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, and a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Our model estimates for Skyrizi and Rinvoq sales are pegged at $4.87 billion and $2.33 billion, respectively, for the to-be-reported quarter.Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC and Rinvoq in giant cell arteritis (GCA) indication, are expected to drive Q4 performance.
Beyond immunology, AbbVie has been expanding its presence in other therapeutic areas, notably neuroscience and oncology. Growth in its neuroscience franchise has been supported by increasing uptake of its oral migraine therapies, Ubrelvy and Qulipta. In oncology, the company has successfully broadened its portfolio beyond hematologic cancers into solid tumors, led by newer assets such as Elahere and Emrelis.
ABBV’s Competition in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Eli Lilly drug received FDA approval for the CD indication last year.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.50 times forward earnings, lower than its industry’s average of 17.91. The stock is also trading above its five-year mean of 13.55.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2025 has declined from $10.73 to $10.64, while those for 2026 have increased from $14.41 to $14.42 over the past 60 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.